Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Cash & Current Investments (2016 - 2025)

Gsk has reported Cash & Current Investments over the past 11 years, most recently at $4.7 billion for Q4 2025.

  • Quarterly results put Cash & Current Investments at $4.7 billion for Q4 2025, down 8.37% from a year ago — trailing twelve months through Dec 2025 was $4.7 billion (down 8.37% YoY), and the annual figure for FY2025 was $4.7 billion, down 8.37%.
  • Cash & Current Investments for Q4 2025 was $4.7 billion at Gsk, down from $5.1 billion in the prior quarter.
  • Over the last five years, Cash & Current Investments for GLAXF hit a ceiling of $9.2 billion in Q4 2022 and a floor of $4.7 billion in Q4 2025.
  • Median Cash & Current Investments over the past 5 years was $5.8 billion (2021), compared with a mean of $6.2 billion.
  • Biggest five-year swings in Cash & Current Investments: tumbled 32.29% in 2021 and later skyrocketed 59.0% in 2022.
  • Gsk's Cash & Current Investments stood at $5.8 billion in 2021, then soared by 59.0% to $9.2 billion in 2022, then crashed by 30.36% to $6.4 billion in 2023, then fell by 19.95% to $5.1 billion in 2024, then decreased by 8.37% to $4.7 billion in 2025.
  • The last three reported values for Cash & Current Investments were $4.7 billion (Q4 2025), $5.1 billion (Q4 2024), and $6.4 billion (Q4 2023) per Business Quant data.